COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Food and Drug Administration has revised its provider and recipient fact sheets for the Johnson & Johnson COVID-19 vaccine due to reports of immune thrombocytopenia (ITP), a disorder that can cause easy or excessive bruising and bleeding due to very low platelet levels.
On Jan. 7, the U.S. Supreme Court held oral argument to consider the injunctions that
blocked the Centers for Medicare & Medicaid Services’ (CMS) rule requiring covered
facilities to ensure that their staff are vaccinated against COVID-19 (subject to medical
and religious exemptions).
The U.S. Supreme Court today held oral arguments on whether to allow the Centers for Medicare & Medicaid Services’ and Occupational Safety and Health Administration’s vaccine mandates to go into effect while appeals are heard in the courts of appeals.
The Centers for Medicare…
The Food and Drug Administration announced that five months is the recommended interval between a primary dosing regimen and booster for Moderna’s COVID-19 vaccine. Previously, the recommended gap was six months.
The Department of Health and Human Services (HHS) today updated its guidance to hospitals on the reporting of COVID-19-related data.
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., recommended 12-15 year olds receive a single booster dose of the Pfizer COVID-19 vaccine at least five months after the initial two-dose series, expanding the agency’s recommendation for 16 and 17 year olds to younger…
COVID-19 vaccination during pregnancy was not associated with greater risk of preterm or small-for-gestational-age birth in a study comparing over 10,000 women who received at least one dose of COVID-19 vaccine during pregnancy with more than 36,000 women who did not, the Centers for Disease…
Two new COVID-19 home tests are now available to consumers in the U.S. Tests from SD Biosensor and Siemens in December gained Food and Drug Administration emergency use authorization, in part driven by the Department of Health and Human Services’ accelerated pathway to support FDA’s review of tests…
The Centers for Disease Control and Prevention announced a pair of changes to its recommendations regarding Pfizer’s COVID-19 vaccine.